Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ahead Of Patent Loss, Takeda’s Actos Benefits From Avandia Drop Off

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Takeda Pharmaceutical's diabetes treatment Actos registered stronger-than-expected sales in the April-September period, benefiting from a price increase in the U.S. and the restricted use or market withdrawal of competitor Avandia

You may also be interested in...



Another Setback For Glitazones: Germany Withdraws Reimbursement For The Diabetes Drugs

Federal joint committee decision means GSK's Avandia and Takeda's Actos no longer will be reimbursed in Germany other than in exceptional cases.

Another Setback For Glitazones: Germany Withdraws Reimbursement For The Diabetes Drugs

Federal joint committee decision means GSK's Avandia and Takeda's Actos no longer will be reimbursed in Germany other than in exceptional cases.

GSK Will End Avandia Promotion Worldwide

Even in countries where the drug will still be sold, the firm projects "minimal" sales.

Related Content

UsernamePublicRestriction

Register

ID1131690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel